Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus.
作者信息
Shaw Katharina, Sanchez-Melendez Stephanie, Taylor Dustin, Barker Julia, LaChance Avery, Shahriari Neda, Vleugels Ruth Ann
机构信息
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Dermatology, University of Vermont Medical Center, Burlington.
出版信息
JAMA Dermatol. 2023 May 1;159(5):560-563. doi: 10.1001/jamadermatol.2023.0175.
Abstract
摘要
相似文献
1
Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus.
JAMA Dermatol. 2023 May 1;159(5):560-563. doi: 10.1001/jamadermatol.2023.0175.
2
Treatment With Anifrolumab for Discoid Lupus Erythematosus.
JAMA Dermatol. 2023 Feb 1;159(2):224-226. doi: 10.1001/jamadermatol.2022.5242.
3
Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus.
Mod Rheumatol Case Rep. 2024 Jul 8;8(2):267-271. doi: 10.1093/mrcr/rxae018.
4
Anifrolumab for Adolescent Discoid Lupus Erythematosus.
JAMA Netw Open. 2023 Oct 2;6(10):e2338200. doi: 10.1001/jamanetworkopen.2023.38200.
5
Improvement in mucosal discoid lupus erythematosus with anifrolumab.
Clin Exp Dermatol. 2023 Sep 19;48(10):1165-1167. doi: 10.1093/ced/llad190.
6
A gyrate pattern of discoid lupus erythematosus.
J Dermatol. 2024 Apr;51(4):e106-e107. doi: 10.1111/1346-8138.17135. Epub 2024 Mar 3.
7
Impressive resolution of refractory hypertrophic discoid lupus erythematosus with anifrolumab.
BMJ Case Rep. 2024 Jun 18;17(6):e258487. doi: 10.1136/bcr-2023-258487.
8
Treatment of discoid lupus with lenalidomide and anifrolumab: Case report and review of the literature.
Lupus. 2024 Nov;33(13):1487-1491. doi: 10.1177/09612033241289489. Epub 2024 Oct 7.
9
Refractory lupus erythematosus tumidus responsive to tildrakizumab.
Dermatol Ther. 2019 Sep;32(5):e13070. doi: 10.1111/dth.13070. Epub 2019 Sep 3.
10
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.
J Am Acad Dermatol. 2023 Jul;89(1):171-173. doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5.
引用本文的文献
1
Anifrolumab for Nonsystemic Cutaneous Lupus Erythematosus: Clinical Experience, Immunologic Insights, and Review of the Literature.
J Clin Med. 2025 Aug 11;14(16):5683. doi: 10.3390/jcm14165683.
2
Cutaneous Lupus Features Specialized Stromal Niches and Altered Retroelement Expression.
J Invest Dermatol. 2025 May 21. doi: 10.1016/j.jid.2025.04.033.
3
Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab.
Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):381-391. doi: 10.31138/mjr.260624.cto. eCollection 2024 Jun.
4
Discoid lupus erythematosus successfully treated with deucravacitinib.
JAAD Case Rep. 2024 Apr 30;49:59-61. doi: 10.1016/j.jdcr.2024.04.032. eCollection 2024 Jul.
5
Anifrolumab for the treatment of refractory chilblain lupus erythematosus.
JAAD Case Rep. 2023 Nov 4;48:69-71. doi: 10.1016/j.jdcr.2023.10.020. eCollection 2024 Jun.
6
An update on clinical trials for cutaneous lupus erythematosus.
J Dermatol. 2024 Jul;51(7):885-894. doi: 10.1111/1346-8138.17161. Epub 2024 Mar 15.
7
Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab.
JAAD Case Rep. 2023 Dec 16;44:71-73. doi: 10.1016/j.jdcr.2023.12.002. eCollection 2024 Feb.
8
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
Lupus Sci Med. 2023 Dec 19;10(2):e001007. doi: 10.1136/lupus-2023-001007.
9
Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature.
Biomedicines. 2023 Oct 26;11(11):2904. doi: 10.3390/biomedicines11112904.
10
Cutaneous Lupus Erythematosus: Review and Considerations for Older Populations.
Drugs Aging. 2024 Jan;41(1):31-43. doi: 10.1007/s40266-023-01079-5. Epub 2023 Nov 22.
Zotero 插件